캐나다 - 영어 - Health Canada

accord healthcare inc - fludarabine phosphate - solution - 25mg - fludarabine phosphate 25mg - antineoplastic agents

나미비아 - 영어 - Namibia Medicines Regulatory Council

teva pharmaceuticals (pty) ltd - fludarabine phosphate - concentrate for solution for injection - each 2 ml vial contains; fludarabine phosphate 50,0 mg

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fludarabine phosphate, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; mannitol - treatment of b-cell chronic lymphocytic leukaemia.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fludarabine phosphate, quantity: 50 mg - injection, powder for - excipient ingredients: mannitol; sodium hydroxide - treatment of b-cell chronic lymphocytic leukaemia.

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

pharmachemie bv - fludarabine phosphate - concentrate for soln for inj - 25 mg/ml - purine analogues

미국 - 영어 - NLM (National Library of Medicine)

accord healthcare, inc. - fludarabine phosphate (unii: 1x9vk9o1sc) (fludarabine - unii:p2k93u8740) -

벨기에 - 영어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - fludarabine phosphate 25 mg/ml - concentrate for solution for injection/infusion - 25 mg/ml - fludarabine phosphate 25 mg/ml - fludarabine

벨기에 - 영어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - fludarabine phosphate 50 mg/2 ml - concentrate for solution for injection/infusion - 25 mg/ml - fludarabine phosphate 25 mg/ml - fludarabine

벨기에 - 영어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - fludarabine phosphate 25 mg/ml - concentrate for solution for injection/infusion - 25 mg/ml - fludarabine phosphate 25 mg/ml - fludarabine

미국 - 영어 - NLM (National Library of Medicine)

actavis pharma, inc. - fludarabine phosphate (unii: 1x9vk9o1sc) (fludarabine - unii:p2k93u8740) - fludarabine phosphate 25 mg in 1 ml - fludarabine phosphate injection, usp is indicated for the treatment of adult patients with b-cell chronic lymphocytic leukemia (cll) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. the safety and effectiveness of fludarabine phosphate injection, usp in previously untreated or non-refractory patients with cll have not been established. none teratogenic effects: pregnancy category d. [see warnings and precautions (5.6)] based on its mechanism of action, fludarabine phosphate can cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of fludarabine phosphate injection in pregnant women, in rats, repeated intravenous doses of fludarabine phosphate at 2.4 times and 7.2 times the recommended human intravenous dose (25 mg/m2 ) administered during organogenesis caused an increase in resorptions, skeletal and visceral malformations (cleft palate, exencephaly, and fetal vertebra